Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02586987
Title A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca

Advanced Solid Tumor


Durvalumab + Selumetinib

Age Groups: adult
Covered Countries USA

No variant requirements are available.